Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Branford

Showing results (421-430 of 480) with videos related to

Pageof 48
Sort By:
Haematologica|February 2, 2023
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysisJerald P Radich, Matthew Wall, Susan Branford, et al.
Haematologica|March 2, 2019
<i>De novo UBE2A</i> mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathwaysVera Magistroni, Mario Mauri, Deborah D'Aliberti, et al.
American Journal of Hematology|May 21, 2024
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysisCamille Kockerols, Peter J M Valk, Stéphanie Dulucq, et al.
Blood|December 19, 2014
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Michael P Osborn, Deborah L White, et al.
Haematologica|March 23, 2023
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment interventionNaranie Shanmuganathan, Carol Wadham, NurHezrin Shahrin, et al.
Blood|March 8, 2024
IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activationLih En Hong, Mihir D Wechalekar, Monika Kutyna, et al.
American Journal of Physiology. Cell Physiology|April 1, 2026
Fibroblast specialisation across microanatomy in a single-cell atlas of human Achilles tendonCarla J Cohen, Jolet Y Mimpen, Alina Kurjan, et al.
Leukemia|May 4, 2007
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurementsJ Saldanha, M Silvy, N Beaufils, et al.
Nature|March 23, 2017
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1Andrew A Wylie, Joseph Schoepfer, Wolfgang Jahnke, et al.
Leukemia|May 16, 2019
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distributionDeepak Singhal, Li Yan A Wee, Monika M Kutyna, et al.
Pageof 48

Showing results (421-430 of 480) with videos related to

Sort By:
Pageof 48
Haematologica|February 2, 2023
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysisJerald P Radich, Matthew Wall, Susan Branford, et al.
Haematologica|March 2, 2019
<i>De novo UBE2A</i> mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathwaysVera Magistroni, Mario Mauri, Deborah D'Aliberti, et al.
American Journal of Hematology|May 21, 2024
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysisCamille Kockerols, Peter J M Valk, Stéphanie Dulucq, et al.
Blood|December 19, 2014
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Michael P Osborn, Deborah L White, et al.
Haematologica|March 23, 2023
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment interventionNaranie Shanmuganathan, Carol Wadham, NurHezrin Shahrin, et al.
Blood|March 8, 2024
IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activationLih En Hong, Mihir D Wechalekar, Monika Kutyna, et al.
American Journal of Physiology. Cell Physiology|April 1, 2026
Fibroblast specialisation across microanatomy in a single-cell atlas of human Achilles tendonCarla J Cohen, Jolet Y Mimpen, Alina Kurjan, et al.
Leukemia|May 4, 2007
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurementsJ Saldanha, M Silvy, N Beaufils, et al.
Nature|March 23, 2017
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1Andrew A Wylie, Joseph Schoepfer, Wolfgang Jahnke, et al.
Leukemia|May 16, 2019
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distributionDeepak Singhal, Li Yan A Wee, Monika M Kutyna, et al.
Pageof 48